← Back to Search

Monoclonal Antibodies

IMM0306 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of study (52 weeks)
Awards & highlights

Study Summary

This trial is testing a new drug, IMM0306-02, for people with B-cell NHL who haven't responded to other treatments or who have relapsed.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of study (52 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study (52 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD) of IMM0306 as measured by incidence of DLTs (Dose Limiting Toxicity)

Trial Design

1Treatment groups
Experimental Treatment
Group I: IMM0306Experimental Treatment1 Intervention
IMM0306 Dose escalation: 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, 0.8mg/kg,1.2mg/kg and 1.6mg/kg through intravenous administration weekly up to 52 weeks.

Find a Location

Who is running the clinical trial?

ImmuneOnco Biopharmaceuticals (Shanghai) Co., LtdLead Sponsor
3 Previous Clinical Trials
277 Total Patients Enrolled
Worldwide Clinical TrialsOTHER
61 Previous Clinical Trials
14,297 Total Patients Enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Lead Sponsor
12 Previous Clinical Trials
1,240 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
2021. "Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04746131.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top